TherapeuticsMD (TXMD) Change in Accured Expenses (2010 - 2026)

TherapeuticsMD (TXMD) has 17 years of Change in Accured Expenses data on file, last reported at $434000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 58.39% year-over-year to $434000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $432000.0 (up 235.42% YoY) and the FY2025 annual result came in at $272000.0, up 127.04% from the prior year.
• Change in Accured Expenses improved to $434000.0 in Q1 2026, from -$237000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $19.1 million in Q3 2022 to a low of -$14.1 million in Q4 2022.
• A 5-year average of -$691235.3 and a median of -$237000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 3282.27% — and 2025, when it slumped 331.82%.
• Tracing TXMD's Change in Accured Expenses over 5 years: stood at -$14.1 million in 2022, then jumped by 73.04% to -$3.8 million in 2023, then jumped by 81.79% to -$691000.0 in 2024, then surged by 65.7% to -$237000.0 in 2025, then jumped by 283.12% to $434000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $434000.0 (Q1 2026), -$237000.0 (Q4 2025), and $425000.0 (Q3 2025), per Business Quant data.